EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Balcinrenone Plus Dapagliflozin in Patients with Heart Failure and Chronic Kidney Disease: Results from the Phase 2b MIRACLE Trial

Carolyn S P Lam, Lars Køber, Koichiro Kuwahara, Lars H Lund, Patrick B Mark, Linda G Mellbin, Morten Schou, Patricia Ely Pizzato, Anders Gabrielsen, Samvel B Gasparyan, Alessandro Ghiretti, Judith Hartleib-Geschwindner und 6 weitere

European Journal of Heart Failure · 2024

DOI: 10.1002/ejhf.3294 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift European Journal of Heart Failure, 2024. Verfasst von Carolyn S P Lam und 17 weiteren Autor:innen. Beteiligte Einrichtung: National Heart Centre, Singapore & Duke-National University of Singapore, Singapore, Singapore. Hauptthemen laut MEDLINE: Heart Failure, Glucosides, Renal Insufficiency, Chronic, Benzhydryl Compounds. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Many patients with heart failure (HF) have chronic kidney disease (CKD) and may not tolerate mineralocorticoid receptor antagonists. We investigated the efficacy and safety of the novel mineralocorticoid receptor modulator balcinrenone in combination with dapagliflozin in a phase 2b study. Methods and results From January 2021 to October 2023, we randomized 133 adults with symptomatic HF, ejection fraction <60%, estimated glomerular filtration rate (eGFR) ≥30 to ≤60 ml/min/1.73 m2 and urinary albumin-to-creatinine ratio (UACR) ≥30 to <3000 mg/g, to receive balcinrenone 15, 50 or 150 mg/day plus dapagliflozin 10 mg/day, or dapagliflozin 10 mg/day plus placebo, for 12 weeks. Enrolment was stopped early because of slow recruitment. Relative reductions in UACR from baseline to week 12 (primary endpoint) were not significantly different between the balcinrenone plus dapagliflozin groups versus dapagliflozin plus placebo. There was no clear balcinrenone dose–response relationship. There were possible dose-dependent increases in serum potassium levels, reduced eGFR in the highest dose group, and non-significant trends towards reduced N-terminal pro-B-type natriuretic peptide levels. Hyperkalaemia adverse events led to discontinuation in two participants receiving balcinrenone plus dapagliflozin and none in those receiving dapagliflozin plus placebo.

Conclusion

While the smaller than planned sample size limits interpretation, we did not see significant reduction in UACR in patients treated with balcinrenone plus dapagliflozin compared with dapagliflozin plus placebo.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureGlucosidesRenal Insufficiency, ChronicBenzhydryl CompoundsDrug Therapy, CombinationGlomerular Filtration RateSodium-Glucose Transporter 2 InhibitorsHumansMaleFemaleMiddle AgedAgedMineralocorticoid Receptor AntagonistsDouble-Blind MethodStroke VolumeTreatment Outcome

Stichwörter der Autor:innen

BalcinrenoneChronic kidney diseaseDapagliflozinHeart failureMineralocorticoid receptorUrinary albumin‐to‐creatinine ratio

Substanzen

dapagliflozinGlucosidesBenzhydryl CompoundsSodium-Glucose Transporter 2 InhibitorsMineralocorticoid Receptor Antagonists

Autor:innen und Institutionen

  • National Heart Centre, Singapore & Duke-National University of Singapore, Singapore, Singapore.
  • Rigshospitalet, Heart Centre, Copenhagen, Denmark.
  • Shinshu University School of Medicine, Department of Cardiovascular Medicine, Matsumoto, Japan.
  • Karolinska University Hospital, Stockholm, Sweden; and Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
  • School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
  • Department of Cardiology, Herlev Hospital, Herlev, Denmark.

Zitieren

APA

Lam, C. S. P., Køber, L., Kuwahara, K., Lund, L. H., Mark, P. B., Mellbin, L. G., Schou, M., Ely Pizzato, P., Gabrielsen, A., Gasparyan, S. B., Ghiretti, A., Hartleib-Geschwindner, J., Housler, G. J., Fanti, P., Leonsson-Zachrisson, M., McMurray, J. J. V., Solomon, S. D., & MIRACLE Study Investigators (2024). Balcinrenone Plus Dapagliflozin in Patients with Heart Failure and Chronic Kidney Disease: Results from the Phase 2b MIRACLE Trial. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.3294

Vancouver

Lam CSP, Køber L, Kuwahara K, Lund LH, Mark PB, Mellbin LG, et al. Balcinrenone Plus Dapagliflozin in Patients with Heart Failure and Chronic Kidney Disease: Results from the Phase 2b MIRACLE Trial. European Journal of Heart Failure. 2024. doi:10.1002/ejhf.3294

BibTeX
@article{Lam2024,
  author = {Lam, Carolyn S P and Køber, Lars and Kuwahara, Koichiro and Lund, Lars H and Mark, Patrick B and Mellbin, Linda G and Schou, Morten and Ely Pizzato, Patricia and Gabrielsen, Anders and Gasparyan, Samvel B and Ghiretti, Alessandro and Hartleib-Geschwindner, Judith and Housler, Greggory J and Fanti, Paolo and Leonsson-Zachrisson, Maria and McMurray, John J V and Solomon, Scott D and MIRACLE Study Investigators, MIRACLE Study Investigators},
  title = {Balcinrenone Plus Dapagliflozin in Patients with Heart Failure and Chronic Kidney Disease: Results from the Phase 2b MIRACLE Trial},
  journal = {European Journal of Heart Failure},
  year = {2024},
  doi = {10.1002/ejhf.3294}
}
Kostenlos starten →